- Karolinska Developments portföljbolag Biosergen får slutligt godkännande att utvärdera läkemedelskandidaten BSG005 i patienter med invasiv svampinfektion
- Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
- Karolinska Development invests in BOOST Pharma, expanding its portfolio
- Karolinska Development breddar sin portfölj genom nyinvestering i BOOST Pharma
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
More ▼
Key statistics
On Thursday, Karolinska Development AB (KDEV:STO) closed at 1.40, 0.14% above its 52-week low of 1.40, set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.44 |
---|---|
High | 1.45 |
Low | 1.40 |
Bid | 1.40 |
Offer | 1.40 |
Previous close | 1.45 |
Average volume | 201.69k |
---|---|
Shares outstanding | 267.52m |
Free float | 92.74m |
P/E (TTM) | 11.63 |
Market cap | 387.37m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of Jul 04 2024 17:00 BST.
More ▼